- Home
- IBRX vs FINV Comparison
IBRX vs FINV Comparison
Compare IBRX & FINV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- FINV
- Stock Information
- Founded
- IBRX 2014
- FINV 2007
- Country
- IBRX United States
- FINV China
- Employees
- IBRX N/A
- FINV N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- FINV Finance: Consumer Services
- Sector
- IBRX Health Care
- FINV Finance
- Exchange
- IBRX Nasdaq
- FINV Nasdaq
- Market Cap
- IBRX 1.9B
- FINV 1.8B
- IPO Year
- IBRX N/A
- FINV N/A
- Fundamental
- Price
- IBRX $2.94
- FINV $7.02
- Analyst Decision
- IBRX Strong Buy
- FINV
- Analyst Count
- IBRX 3
- FINV 0
- Target Price
- IBRX $13.58
- FINV N/A
- AVG Volume (30 Days)
- IBRX 6.3M
- FINV 557.3K
- Earning Date
- IBRX 11-12-2024
- FINV 11-18-2024
- Dividend Yield
- IBRX N/A
- FINV 3.38%
- EPS Growth
- IBRX N/A
- FINV N/A
- EPS
- IBRX N/A
- FINV 1.19
- Revenue
- IBRX $7,332,000.00
- FINV $1,837,029,436.00
- Revenue This Year
- IBRX $2,515.60
- FINV $6.61
- Revenue Next Year
- IBRX $766.19
- FINV $7.97
- P/E Ratio
- IBRX N/A
- FINV $5.90
- Revenue Growth
- IBRX 1218.71
- FINV 2.92
- 52 Week Low
- IBRX $2.28
- FINV $4.45
- 52 Week High
- IBRX $10.53
- FINV $7.29
- Technical
- Relative Strength Index (RSI)
- IBRX 48.30
- FINV 59.83
- Support Level
- IBRX $2.28
- FINV $6.91
- Resistance Level
- IBRX $2.54
- FINV $7.12
- Average True Range (ATR)
- IBRX 0.25
- FINV 0.20
- MACD
- IBRX 0.10
- FINV 0.01
- Stochastic Oscillator
- IBRX 64.71
- FINV 84.33
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About FINV FinVolution Group
FinVolution Group is a provider of online consumer finance in China. It offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers Tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company provides investors with an opportunity to invest in emerging asset class-consumer loans through a variety of investment options. It generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC and its revenues are derived from within the PRC.